Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-POLD1 Antibody (R1T53)

Catalog #:   RHD78702 Specific References (11) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: FCM, IF, IHC, WB
Accession: P28340
Overview

Catalog No.

RHD78702

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

FCM: 1:20-1:100, IF: 1:50-1:200, IHC: 1:100-1:200, WB: 1:1000-1:2000

Target

3'-5' exodeoxyribonuclease, DNA polymerase subunit delta p125, POLD1, DNA polymerase delta catalytic subunit, POLD

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P28340

Applications

FCM, IF, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R1T53

Data Image
  • Western blot
    All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.
  • Western blot
    All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.
  • Western blot
    Western blot analysis of DNA Polymerase delta, catalytic subunit expression in (1) Jurkat cell lysate; (2) Raw264.7 cell lysate; (3) C6 cell lysate.
References

The protein deacetylase HDAC10 controls DNA replication in malignant lymphoid cells., PMID:40301616

A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation., PMID:39218995

Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study., PMID:38852601

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer., PMID:38777726

An arrayed CRISPR screen of primary B cells reveals the essential elements of the antibody secretion pathway., PMID:36860866

Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway., PMID:34371300

Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial., PMID:29763623

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine., PMID:28846956

High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations., PMID:28405512

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review., PMID:27310809

Role of the carboxy terminus of herpes simplex virus type 1 DNA polymerase in its interaction with UL42., PMID:7964622

Datasheet

Document Download

Anti-POLD1 Antibody (R1T53).pdf

 

$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-POLD1 Antibody (R1T53) [RHD78702]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only